```html
Nabriva Therapeutics plc is a commercial-stage biopharmaceutical company focused on developing novel antibiotics for serious infections. The company's products include Xenleta (lefamulin), which has been approved by the FDA for both oral and IV use, and CONTEPO (fosfomycin), for which an NDA has been submitted for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP).
The company was founded in 2006 and operates in the biotechnology and health care industries. It is headquartered in Dublin, Ireland, with offices and labs in Vienna, Austria and King of Prussia, PA. Nabriva also has locations in San Diego, CA.
The most recent investment in Nabriva Therapeutics was a Post-IPO Equity investment on 01 March 2021. The investors involved in this round are undisclosed.
```| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | Unknown | - | 01 Mar 2021 | |
| Post-IPO Debt | Unknown | - | 21 Dec 2018 | |
| Post-IPO Equity | Unknown | - | 19 Dec 2016 | |
| Series B | Unknown | - | 07 Apr 2015 | |
| Venture - Series Unknown | Unknown | - | 31 Dec 2014 |
No recent news or press coverage available for Nabriva Therapeutics plc.
We care about your data, and we'd love to use cookies make your experience better.
